SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors gear up for the company's upcoming earnings report, with the community actively debating the strength of its massive contracted backlog versus broader market volatility and macro concerns. Discussions are heavily focused on the company's ability to convert long-term hyperscaler agreements into sustainable revenue and cash flow, as traders look for any sign of further infrastructure expansion.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing significant market volatility after FDA briefing documents challenged the statistical methods and efficacy of its DMD therapy, Deramiocel. While the company is actively pushing back by citing the use of obsolete analysis plans by the FDA, investors remain sharply divided as they await the outcome of the upcoming advisory committee meeting.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors debate the potential impacts of aggressive tariff policies and ongoing geopolitical tensions involving Iran. The community remains deeply polarized, with active discussion focusing on the platform's long-term business viability, the broader economic consequences of current administration actions, and high levels of volatility surrounding the stock.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is surging following a massive earnings beat and upward guidance revision, fueled by explosive demand for its AI data center infrastructure, particularly for hyperscaler TPU programs. The community is buzzing over the company's ability to maintain high growth rates and margin expansion, with many active traders viewing the stock as a prime beneficiary of long-term AI infrastructure spending despite recent sector volatility.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as investors weigh an ongoing patent infringement lawsuit against the company's strategic pivot toward AI infrastructure and power semiconductors. Community sentiment is deeply divided, with many traders focused on the stock's recent volatility and the potential impact of future guidance on its long-term growth prospects.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as investors digest a strong quarterly earnings report that featured a record performance, though the stock faced volatility as the market weighed the results against guidance and broader semiconductor sector sentiment. The community is focused on Amkor's critical role in the AI supply chainspecifically in advanced chip packagingwhile debating the potential for long-term growth versus short-term price swings following recent earnings.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is drawing significant attention as investors react to a $1.57 million NSF grant and the company's recognition as a "Leader" in recent industry assessments. While the community is actively debating the stock's future amid sector-wide volatility, sentiment remains divided between those viewing the pullback as a buying opportunity in a strategic security sector and skeptics concerned about valuation and insider selling.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

MapLight Therapeutics Inc.

MapLight Therapeutics is seeing significant volatility following mixed topline results from its Phase 2 ZEPHYR trial, which hit its primary endpoint but missed once-daily dosing goals. The community is actively debating whether the sharp sell-off represents an institutional overreaction or a fundamental disappointment, with many investors focused on the company's remaining cash position and potential for a rebound.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility driven by the upcoming expiration of its post-listing lockup period, which has led to intense community debate regarding its premium over net asset value (NAV) and potential for further price adjustments. Investors are actively discussing the fund's major AI and aerospace holdings like Anthropic and SpaceX, with conflicting sentiment between those betting on the fund as a strategic proxy for high-profile IPOs and those warning of a disconnect from fundamental valuations.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors monitor significant power infrastructure initiatives, particularly its strategic role in supporting AI data center build-outs like the large-scale generation projects for Applied Digital. Community sentiment remains focused on the company's backlog growth and the potential for new contract announcements, even as market participants debate the stock's volatility ahead of its upcoming earnings report and the impact of broader sector developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

Key PointsA director of Enliven Therapeutics reported selling 10,000 shares in open-market transactions on June 5, 2026, for a total value of $345,000...

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally...

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full...

These Are the Stocks Traders Are Watching into the Close

As the market enters the final stretch of trading, one story is dominating virtually every trading desk on Wall Street: the historic debut of SpaceX. The company's long-awaited public offering has generated extraordinary volume, massive investor interest, and renewed enthusiasm across multiple high-growth sectors including space infrastructure, artificial intelligence, biotechnology, and advanced communications. $NTHI, $SPCX, $ELVN, $POET, $RNAC, $ALOY

ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development

Equity

As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried multiple existing therapies, Enliven Therapeutics said.


Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire BURLINGAME, Calif., June 11, 2026 BURLINGAME, Calif., June 11, 2026...

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire BURLINGAME, Calif., June 11, 2026 BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven...

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components PR Newswire BURLINGAME, Calif...

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress PR Newswire BURLINGAME, Calif...

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.

Key PointsChief Medical Officer Helen Collins sold 5,000 shares of Common Stock for a total of ~$199,000 on May 18, 2026, at an average price of around $39.79 per share...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Enliven Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

The Fed's July 28-29 meeting has markets debating a hold versus a hike, not a cut, with CME FedWatch pricing roughly a 65% chance of no change and rising odds of a September rate increase amid inflation running well above the 2% target. What do you expect the Fed to decide? Drop a comment with when you expect the first cut/hike to be.

What do you expect the Fed to decide at its FOMC meeting?  
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ELVNEnliven Therapeutics Inc

Fundamentals

Latest ELVN News